Announcements Trials

Browse Landscape

Phase

Phase NA 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pain, Postoperative 3 Neoplasms 2 Warts 1 Urinary Bladder Neoplasms 1 Spinal Cord Neoplasms 1 Shock, Septic 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pleural Effusion 1 Papillomavirus Infections 1 Liver Neoplasms 1 Depression 1 Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 6 Carboplatin 3 valrubicin 2 Cisplatin 2 vinflunine 1 toripalimab 1 pertuzumab 1 disitamab vedotin 1 cabazitaxel 1 apaziquone 1 XRP6258 1 Watchful Waiting 1 Vinblastine 1 Trastuzumab 1 Transurethral Resection of Bladder 1 Tranexamic Acid 1 Saline Solution 1 RC48 antibody 1 Oncolytic Virotherapy 1 Mitomycin 1 Methotrexate 1 Magnetic Resonance Spectroscopy 1 Lapatinib 1 Interferons 1 Interferon-alpha 1 Gabapentin 1 Circulating Tumor DNA 1 Celecoxib 1 BCG Vaccine 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Urinary Bladder Neoplasms × Saline Solution × Clear all

NCT01869413 2022-10-04

TACT

Ottawa Hospital Research Institute

Phase 2/3 Completed

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡